14-day Premium Trial Subscription Try For FreeTry Free
RSI low/high Values: [ 25 - 75 ]
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
AI Analysis of CADL
Powered by GPT-4
Upgraded!
Stock Analysis
Risk Assessment
Trading Strategy

Volatile ride for Candel Therapeutics, Inc. stock price on Tuesday moving between $8.66 and $9.63
(Updated on May 07, 2024)

Buy or Hold candidate since Apr 01, 2024 Gain 448.00% PDF

The Candel Therapeutics, Inc. stock price gained 8.36% on the last trading day (Tuesday, 7th May 2024), rising from $8.85 to $9.59. During the last trading day the stock fluctuated 11.20% from a day low at $8.66 to a day high of $9.63. The price has risen in 8 of the last 10 days and is up by 62.27% over the past 2 weeks. Volume fell on the last day by -1 million shares and in total, 761 thousand shares were bought and sold for approximately $7.30 million. You should take into consideration that falling volume on higher prices causes divergence and may be an early warning about possible changes over the next couple of days.

The stock has broken the very wide and strong rising the short-term trend up and an even stronger rate of rising is indicated. For any reaction back there will now be support on the roof on the current trend broken at $9.47, a level that may pose a second chance to hit a runner. According to fan-theory $13.28 will be the next possible trend-top level and thereby pose a resistance level that may not be broken at the first attempt.

Ready to grow your portfolio? Here's your beginner's guide to opening a free brokerage account.

CADL Signals & Forecast

The Candel Therapeutics, Inc. stock holds buy signals from both short and long-term Moving Averages giving a positive forecast for the stock. Also, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average. On corrections down, there will be some support from the lines at $8.19 and $5.04. A breakdown below any of these levels will issue sell signals. A buy signal was issued from a pivot bottom point on Friday, April 19, 2024, and so far it has risen 85.49%. Further rise is indicated until a new top pivot has been found. Volume fell during the last trading day despite gaining prices. This causes a divergence between volume and price and it may be an early warning. The stock should be watched closely. Some negative signals were issued as well, and these may have some influence on the near short-term development. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD).

Support, Risk & Stop-loss for Candel Therapeutics, Inc. stock

On the downside, the stock finds support just below today's level from accumulated volume at $8.85 and $8.43. There is a natural risk involved when a stock is testing a support level, since if this is broken, the stock then may fall to the next support level. In this case, Candel Therapeutics, Inc. finds support just below today's level at $8.85. If this is broken, then the next support from accumulated volume will be at $8.43 and $7.28.

This stock may move very much during the day (volatility) and with a very large prediction interval from the Bollinger Band this stock is considered to be "very high risk". During the last day, the stock moved $0.97 between high and low, or 11.20%. For the last week, the stock has had daily average volatility of 17.11%.

The Candel Therapeutics, Inc. stock is extremely overbought on RSI14 (90). Normally this may pose a good selling opportunity but since the stock has broken the trend up, the chance for a major correction due to high RSI is very small as the stock will find support at the trend broken.

Our recommended stop-loss: $9.33 (-2.70%) (This stock has very high daily movements and this gives very high risk. The RSI14 is 90 and this increases the risk substantially. There is a buy signal from a pivot bottom found 12 days ago.)

Trading Expectations (CADL) For The Upcoming Trading Day Of Wednesday 8th

For the upcoming trading day on Wednesday, 8th we expect Candel Therapeutics, Inc. to open at $9.29, and during the day (based on 14 day Average True Range), to move between $8.56 and $10.62, which gives a possible trading interval of +/-$1.03 (+/-10.77%) up or down from last closing price. If Candel Therapeutics, Inc. takes out the full calculated possible swing range there will be an estimated 21.55% move between the lowest and the highest trading price during the day.

With no resistance above and support from accumulated volume @ $8.85, some $0.740 (7.72%) from the current price of $9.59, our system finds the risk reward attractive.

Earnings coming up

Candel Therapeutics, Inc. will release earnings BMO on Thursday, May 09, 2024. We will update the financials statements for Candel Therapeutics, Inc., that can be found here as soon as the records are public. Our systems has calculated a possible swing of +/- 8.85% in the first trading day after earnings release.

Is Candel Therapeutics, Inc. stock A Buy?

Candel Therapeutics, Inc. holds several positive signals and has broken the strong rising trend up. As the stock is also in great technical shape we, therefore, consider it to be a good choice at these current levels and we are expecting further gains during the next 3 months. We have upgraded our analysis conclusion for this stock since the last evaluation from a Buy to a Strong Buy candidate.

Current score: 6.281 Strong Buy Candidate Upgraded

Predicted Opening Price for Candel Therapeutics, Inc. of Wednesday, May 8, 2024

Fair opening price May 8, 2024 Current price
$9.29 ( 3.09%) $9.59

The predicted opening price is based on yesterday's movements between high, low, and closing price.

Trading levels for CADL

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 10.26 7.02 %
R2 9.89 3.16 %
R1 9.66 0.770 %
Current price: 9.59
Support S1 8.92 -6.96 %
S2 8.69 -9.34 %
S3 8.32 -13.21 %

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 0 .
R2 0 .
R1 0 .
Current price 9.59
Support S1 8.85 -7.72%
S2 8.43 -12.10%
S3 7.28 -24.09%

FAQ

What is the symbol for Candel Therapeutics, Inc. Stock and on which exchange is it traded?
The symbol for Candel Therapeutics, Inc. is CADL and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell Candel Therapeutics, Inc. Stock?
Candel Therapeutics, Inc. holds several positive signals and has broken the strong rising trend up. As the stock is also in great technical shape we, therefore, consider it to be a good choice at these current levels and we are expecting further gains during the next 3 months. We have upgraded our analysis conclusion for this stock since the last evaluation from a Buy to a Strong Buy candidate.

How to buy Candel Therapeutics, Inc. Stock?
Candel Therapeutics, Inc. Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy Candel Therapeutics, Inc. Stock.

What's the current price of Candel Therapeutics, Inc. Stock?
As of the end of day on the May 07, 2024, the price of an Candel Therapeutics, Inc. (CADL) share was $9.59.

What is the 52-week high and low for Candel Therapeutics, Inc. Stock?
The 52-week high for Candel Therapeutics, Inc. Stock is $11.40 and the 52-week low is $0.660.

What is the market capitalization of Candel Therapeutics, Inc. Stock?
As of the May 07, 2024, the market capitalization of Candel Therapeutics, Inc. is 281.443M.

When is the next earnings date for Candel Therapeutics, Inc.?
The upcoming earnings date for Candel Therapeutics, Inc. is May 09, 2024.
Click to get the best stock tips daily for free!

About Candel Therapeutics, Inc.

Candel Therapeutics. Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of hi... CADL Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT